Personalized 1st-line Treatment of Patients With NSCLC: is Timely Analysis of EGFR-mutation Status Feasible in a Routine Practice Setting in Antwerp.
18 Years
N/A
Both
Non Small Cell Lung Cancer
Trial Information
Personalized 1st-line Treatment of Patients With NSCLC: is Timely Analysis of EGFR-mutation Status Feasible in a Routine Practice Setting in Antwerp.
The favourable results of a number of phase III-trials with gefitinib in NSCLC patients with
activating EGFR-mutations, have resulted in the licensing of gefitinib in this indication.
This offers the prospect of a true personalized treatment of patients with NSCLC.
Implementation of such a personalized treatment strategy is dependent both on the
availability of adequate tumor samples for the EGFR-mutation analysis and on the timely
reporting of the mutation analysis results. Ideally the results should be available in all
patients within 2 weeks of the analysis request.
Inclusion Criteria:
- age 18 years or above
- newly diagnosed NSCLC
- written informed consent
- tumor sample available
Exclusion Criteria:
- mixed histology of small cell and NSCLC
Type of Study:
Observational
Study Design:
Observational Model: Case-Only, Time Perspective: Prospective
Outcome Measure:
testing turn around time (in days)
Outcome Description:
how long does it take to get the mutation analysis result
Outcome Time Frame:
up to 1 month
Safety Issue:
No
Principal Investigator
Paul R Germonpre, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
UZA + Thoracale Oncologie Groep Antwerpen
Authority:
Belgium: Institutional Review Board
Study ID:
TOGA 1001
NCT ID:
NCT01260038
Start Date:
November 2010
Completion Date:
September 2011
Related Keywords:
- Non Small Cell Lung Cancer
- Non Small Cell Lung Cancer
- observational study
- EGFR mutation analysis
- EGFR mutation status
- testing turn around time
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
Name | Location |
|---|
